Kiromic BioPharma, Inc. (KRBP)
| Previous close | 0.0000 |
| Open | 1.9400 |
| Bid | 1.8000 x 40000 |
| Ask | 2.0500 x 40000 |
| Day's range | 1.7900 - 1.9500 |
| 52-week range | 0.1600 - 3.7800 |
| Volume | |
| Avg. volume | 3,162 |
| Market cap | 2.761M |
| Beta (5Y monthly) | 1.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -7.4200 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase
HOUSTON, July 18, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces plans to advance the Deltacel-01 Phase 1 clinical trial to the Expansion Phase following a positive assessment from the Deltacel-01 Safety Monitoring Committee (SMC). The SMC convened on July 16th and reviewed safety and efficacy data collected to-date in Deltacel-01, confirming favorable results and optimal dose.
- Business Wire
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
HOUSTON, June 20, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.
- Business Wire
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
HOUSTON, June 06, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies.
